Retatrutide vs Tirzepatide: Mechanism, Efficacy, Dosing & Cost (2026)

Important: This is a research-focused comparison, not medical advice. The trial figures below are study outcomes, not dosing recommendations. Retatrutide is investigational and not FDA-approved; tirzepatide is approved only as the prescription drugs Mounjaro and Zepbound. Research-grade peptides are sold for laboratory research purposes only. Consult a licensed healthcare professional before using any compound.

Retatrutide and tirzepatide are the two most-discussed next-generation incretin peptides — and the question everyone asks is simple: which one is stronger, and is the newer one worth it? The short version is that retatrutide adds a third hormonal target and posted larger weight-loss numbers in trials, but it's still investigational, while tirzepatide is the proven, approved option. Here's the honest head-to-head.

Retatrutide vs tirzepatide at a glance#

How they work#

Both peptides are incretin mimetics — they imitate gut hormones that regulate appetite, insulin, and gastric emptying. The difference is how many receptors they hit.

Tirzepatide is a dual agonist: it activates the GLP-1 and GIP receptors. GLP-1 curbs appetite and slows stomach emptying; adding GIP appears to improve the metabolic response beyond GLP-1 alone.

Retatrutide is a triple agonist: it does everything tirzepatide does and adds glucagon-receptor activity. Glucagon agonism increases energy expenditure and can enhance fat mobilization — the leading theory for why retatrutide produced larger losses in trials. The trade-off is that glucagon activity can also nudge heart rate and glucose handling, which is part of why it's still under study.

Efficacy: what the trials show#

This is where retatrutide looks impressive — with an important caveat.

• Tirzepatide (SURMOUNT-1): the 15 mg dose produced a mean body-weight reduction of about 20.9% over 72 weeks, with 43% of participants losing at least 15% (Jastreboff et al., NEJM 2022).
• Retatrutide (Phase 2): the 12 mg dose produced a mean reduction of about 24.2% at 48 weeks — and the curve hadn't fully plateaued (Jastreboff et al., NEJM 2023).

The honest caveat: these are separate trials of different length (48 vs 72 weeks) and different phases (2 vs 3) — there is no published head-to-head trial of retatrutide against tirzepatide. So while retatrutide's numbers are higher, this isn't an apples-to-apples result. Tirzepatide's data is more mature and confirmed across multiple large Phase 3 studies; retatrutide's is earlier-stage but trending higher.

Side effects and safety#

The two share the incretin-class side-effect profile: nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation and usually improving over time. Gradual titration is the standard mitigation in trials.

Retatrutide's distinguishing safety note is its glucagon activity, which was associated with dose-dependent increases in heart rate in the Phase 2 trial (Jastreboff et al., NEJM 2023). Both compounds warrant attention to glucose levels. Because retatrutide is investigational, its long-term safety profile is simply less established than tirzepatide's — a real consideration, not a footnote.

Research dosing and reconstitution#

Both ship as a lyophilized powder and are reconstituted with bacteriostatic water before measuring. In trials, both used a slow weekly dose-escalation schedule to limit GI side effects rather than starting at the top dose. Because each vial's concentration depends on how much BAC water you add, use our reconstitution calculator to convert a target dose into exact syringe units, and the step-by-step reconstitution guide for technique. As always, the trial doses cited here are study figures, not protocols.

Cost and where to buy (research use)#

This is the gap nobody else fills: most comparison pages say retatrutide is "not available" because it isn't an approved drug — but research-grade material is, and the real question is cost per mg. We track live vendor pricing so you can compare directly. Peptide Supply Co. is our top-rated source; research-grade peptides are sold strictly for laboratory research use (not for human consumption).

For full vendor reviews, COAs, and bulk pricing, see where to buy retatrutide and where to buy tirzepatide.

Retatrutide vs tirzepatide vs semaglutide#

Adding the original GLP-1 for context: by trial magnitude the order is retatrutide (~24%) > tirzepatide (~21%) > semaglutide (~15%) (semaglutide STEP 1, NEJM 2021). But maturity runs the other way — semaglutide and tirzepatide are approved with long safety records, while retatrutide is still investigational. Semaglutide remains the most available and longest-studied; tirzepatide is the strongest approved option; retatrutide is the strongest on paper but earliest-stage. For the full field, see our best peptides for weight loss guide.

Frequently asked questions